About Conferences

Conference Series invites all the participants across the globe to 12th  International Conference on Cancer & Tumor Immunology February 14-15, 2022 Toronto Canada Which deals with the advanced topics related to Cancer Immunology, Tumor Immunology Cancer and Tumor Research and therapy, Novel approaches in Cancer and Tumor , Infectious Diseases, Epidemiology and prevention, Healthcare delivery, Information, patients and the public which will cover the topics like Research Education and communication about cancer, Public policy issues, ethics and confidentiality Cancer Biology and model systems, the tumor microenvironment etc.

The Main theme of the conference is “Discover the Potentials in the Pitch of Cancer and Tumor”.

Cancer Immunology 2022 will mainly target Fellows, Immunologists, oncologist’s nurse practitioners, nurses, pharmacist, physician assistants, researchers, and other health care professionals interested in the treatment of cancer and Tumor. Cancer Immunology 2022 conference acts as a bridge between academics and business to offer them a common platform to interact and share ideas.

why to attend

Cancer immunology offers the best and advanced technologies around the world focused on learning about Cancer and Immunology and its advances: this is your best opportunity to reach the largest assemblage of participants from Cancer Immunology community. conduct presentations, distribute information’s, meet with current and potential scientists, make a splash with new drug developments, and receive name recognition at this 2-day event, world renowned speakers, the most recent techniques, developments, and the newest updates in Cancer immunology are hallmarks of this conference.

Sessions/Tracks

Track 1: Cancer Immunology:

Cancer Immunology will outline the basic biology of immune responses with the goal of developing new immune therapy approaches and improving existing ones. Basic research to investigate, at the cellular and molecular levels, the mechanisms that regulate the immune system, yielding knowledge that will further our efforts to harness the power of the immune system to treat cancer.

Cancer Conferences | Cancer Immunology Conferences | Immunology Conferences

Track 2: Tumor Immunology

Tumor Immunology is determining the function and behaviors of innate and adaptive immune cells in health and disease, including the interactions with their microenvironment. Understanding the essential principles underlying immune cell development, activation, regulation, differentiation and death also because the molecular mechanisms underlying diversity and plasticity of the system may be a prerequisite for the planning of targeted manipulation strategies to guard from cancer, autoimmunity and infection and to foster and devise the event of novel therapeutic approaches. To address their research questions the individual groups, develop and use sophisticated experimental model systems and technologies like structural biology, genetic barcoding and high-throughput single cell analysis platforms.

Cancer Conferences | Cancer Immunology Conferences | Immunology Conferences

Track 3: Immunology & Immunotherapy

Covers all areas of immunology including cellular and molecular immunology, immunochemistry, immunogenetics, imaging, mathematical modelling, allergy, transplantation immunology, cancer immunology, clinical immunology and immunological therapies, physiological functioning of the immune system in states of both health and disease, malfunctions of the immune system in immunological disorders and therapies (autoimmune diseases, hypersensitivities, immune deficiency, transplant rejection), the physical, chemical and physiological characteristics of the components of the immune system in vitro, in situ, and in vivo are of prime interest.

Cancer Conferences | Cancer Immunology Conferences | Immunology Conferences

Track 4: Inflammation and Cancer

Prolonged inflammation can damage your body’s healthy cells and tissue, and weaken your immune system, the link between inflammation and cancers, cancers tended to occur at sites of chronic inflammation. Lately, it turned out that acute inflammation contributed to the regression of cancer. Inflammation and innate immunity are important targets in patients with cancer

Cancer Conferences | Cancer Immunology Conferences | Immunology Conferences

Track 5: Cancer & HIV

People with HIV/AIDS are at high risk for developing certain cancers, such as Kaposi's sarcoma, non-Hodgkin lymphoma, and cervical cancer. For people with HIV, these three cancers are often called "AIDS-defining conditions. Most types of cancer begin when normal cells begin to change and grow uncontrollably, forming a mass called a tumor. A tumor can be benign (noncancerous) or malignant (cancerous, meaning it can spread to other parts of the body).

Cancer conferences | Cancer Immunology conferences | Immunology Conferences

Track 6: Tumor Microenvironment

Cancers are not just masses of malignant cells but complex ‘rogue’ organs, to which many other cells are recruited and can be corrupted by the transformed cells. Interactions between malignant and non-transformed cells create the tumor microenvironment. Changes of the tumor micro environment have been closely correlated to cancer-mediated inflammation.

Cancer Conferences | Cancer Immunology Conferences | Immunology Conferences

Track 7: Cancer vaccines

A cancer vaccine is a vaccine that treats   with existing cancer or prevents development of a cancer. Cancer vaccines are also   known as biological response modifiers. A biological response modifier helps by stimulating or restoring the immune system’s ability to fight infections and disease. The most commonly used side effect of cancer vaccines is inflammation at the site of injection, including redness, pain, swelling, warming of the skin, itchiness, and occasionally a rash. Mainly these vaccines include cell therapy and gene therapy.

Cancer Conferences | Cancer Immunology Conferences | Immunology Conferences

Track 8: Cancer Prognosis:

Cancer prognosis gives us information about the percentage of people who survive a certain type of cancer for specific amount of time. Some of the factors that affect prognosis like type of cancer, its location in the body, stage, size of the cancer, cancer’s grade and age of the patients etc… The time of period varies; it may be 1 year, 2 years, 5 years, and etc... Cancer-specific survival is also called as Disease-specific survival. There are different ways to measure and report survival and statistics of cancer. This cancer prognosis that mainly include liver cancer prognosis, metastatic prognosis and brain cancer prognosis.

Cancer Conferences | Cancer Immunology Conferences | Immunology Conferences

Track 9: Cancer Cell Biology

Cancer cell biology can be defined as a disease of the genes. This is the small part of DNA and master molecule of the cell. The main two characteristics are uncontrolled growth of the cells in the human body and the ability of these cells to migrate and spread to distant sites. If the spread is not controlled, cancer can result in death. Bone marrow stromal stem cells also called mesenchyme stem cells or skeletal stem cells and these can generate bone, cartilage, and fat cells. The cancer pathology is a medical document that written by a pathologist. A pathologist is a doctor who specializes in interpreting laboratory tests and evaluating cells, tissues, and organs to diagnose disease.

Cancer Conferences | Cancer Immunology Conferences | Immunology Conferences

Track 10: Tumor biology

Cells may acquire mutations in genes that control proliferation, such as tumor suppressor genes. Tumors grow in a series of steps. The first step is hyperplasia, resulting from uncontrolled cell division. These cells appear normal, but some changes occurred that results in loss of control of growth. The second step is dysplasia, resulting from further growth, accompanied by abnormal changes to the cells. The third step requires additional changes, which result in cells that are even more abnormal and can now spread over a wider area of tissue. These cells begin to lose their original function; such cells are called anaplastic. At this stage, the tumor is still contained within its original location (called in situ) and is not invasive, it is not considered malignant - it is potentially malignant. The last step occurs when the cells in the tumor metastasize, which means that they can invade surrounding tissue, including the bloodstream, and spread to other locations. This is the most serious type of tumor, but not all tumors progress to this point. These Tumor Biology that mainly Include Molecular and Cellular oncology and ImmunoOncology.

Cancer conferences | Cancer Immunology conferences | Immunology Conferences

Track 11: Economic Impact on Cancer

Cancer care costs are a financial burden to patients, their families, and society as a whole. In 2006 medical expenses from cancer care in the United States were an estimated $104.1 billion. Cancer can be a major cause of lack of money. This may be due either to the costs of treating and managing the illness as well as its impact upon people's ability to work. This particularly affects countries that lack comprehensive social health insurance systems and other types of social safety nets. The study is a longitudinal short study of 10,000 hospital patients with a first-time diagnosis of cancer. Patients were assigned a socioeconomic status according to the district of residence at diagnosis. Continuity of patients due to cancer living in the most deprived district was compared to survival of patients living in all other districts by model-based period analysis. These major regional socioeconomic inequalities indicate a potential for improving cancer care and survival in Germany. Studies on individual patient data with access to treatment information should be conducted to examine the reasons for these socioeconomic inequalities in cancer survival in more detail.

Cancer conferences | Cancer Immunology conferences | Immunology Conferences

Track 12: Cancer Research

The goal of the Cancer Research Program is to make significant improvements in the prevention, early detection, diagnosis and treatment of cancer. Research into the cause of cancer involves many different disciplines including genetics, diet, environmental factors (i.e., chemical carcinogens).  And it will continue to translate basic research findings into clinical applications together with strategic partners, with the National Centre for Tumor Diseases (NCT) and the nationally active German Consortium for Translational Cancer Research (DKTK) playing key roles. The program is also developing new approaches in the fields of cancer genome and epigenome research, metabolic dysfunction, personalized radiation oncology and ion therapy, molecular imaging, neuro-oncology, individualized cancer medicine and health economics.

Cancer conferences | Cancer Immunology conferences | Immunology Conferences

Track 13: Immuno-Oncology Studies

 Immuno-oncology therapies activate our immune system, making it able to recognize cancer cells and destroy them. Breast cancer is one of the major cancer types for which new immune-based cancer treatments are currently in development. Lung cancer surgery carries risks, including bleeding and infection. Clinical trials are studies of experimental lung cancer treatments. The immune system is the body’s natural defense system. It is a collection of organs, cells and special molecules that helps protect you from infections, cancer and other diseases. Adult central nervous system tumor is a disease in which abnormal cells form in the tissues of the brain and/or spinal cord. A tumor that starts in another part of the body and spreads to the brain is called a metastatic brain tumor. There are different types of brain and spinal cord tumors such as Astrocytic Tumors, Oligodendroglia Tumors, Mixed Gliomas, Ependymal Tumors, Medulloblastomas, Pineal Parenchymal Tumors, Meningeal Tumors, Germ Cell Tumors and Craniopharyngioma. Advances in Immuno-oncology have given oncologists and their patients reason to be encouraged—the launch of immune checkpoint inhibitors and development of other immunotherapy assets for the treatment of several difficult-to-treat diseases, including metastatic melanoma and non-small cell lung cancer, represents great progress.

Cancer conferences | Cancer Immunology conferences | Immunology Conferences

Track 14: Novel Approaches in Cancer & Tumor

The epidermal growth factor receptor (EGFR) autocrine pathway contributes to a number of processes important to cancer development and progression, including cell proliferation, apoptosis, and angiogenesis. Immunotherapy encompasses several different treatment approaches, each of which has a distinct mechanism of action, and all of which are designed to boost or restore immune function in some manner.  This includes: Monoclonal antibodies, Immune checkpoint inhibitors, Therapeutic Cancer vaccines, cytokines, and other non-specific immunotherapies. And mainly includes Metabolomics in Novel Biomarker Discovery.

Cancer Conferences | Cancer Immunology Conferences | Immunology Conferences

Target Audience

Immunologists

Scientists

Oncologists

Research Professors

Physicians

Cancer Research Students

Immunology research students

Pharmacists

Business Entrepreneurs

Medical Colleges

Market Analysis

Cancer Immunology Market Overview 2030:

The global cancer immunology market size was valued at $85,603.50 million in 2020, and is projected to reach $309,667.65 million by 2030, registering a CAGR of 14.1% from 2021 to 2030.

The COVID-19 pandemic has drastically affected buying capacity of hospitals, especially small-scale hospitals and scanning centres. According to an article by Cigna, there has been reductions in hospitalizations for non-elective conditions such as acute coronary syndromes and transient ischemic attacks that raise the possibility that patients may be deferring necessary elements of clinical care. The clinical trials of the new cancer immunotherapy drugs are kept on hold, as during this crisis the individual is more susceptible to suffer from COVID-19. COVID friendly cancer treatment however, are observed to be increased during the course of time and would propel in the coming years. Thus, the COVID-19 pandemic is anticipated to have a negative impact on the cancer immunotherapy market.

Cancer immunotherapy is a cancer treatment that enhances the immune system's ability to fight cancer. This therapy is preferable than the old technique because it provides long-term cancer protection, has less side effects, and treats a wider range of cancer. Cancer immunotherapy is used in different types of cancers such as melanoma, prostate cancer, breast cancer, colorectal cancer, lung cancer, head & neck cancer, and more. Immunotherapy works by directing the immune system toward cancer-specific targets, activating the immune system to mobilize the target, and triggering a response capable of destroying cancer cells. 

There are many factors, such as increase in healthcare expenditure, rise in incidence of cancer, surge in access to medical insurance, and surge in technological advancements in cancer treatment therapies expected to propel the growth of the global cancer immunotherapy market. According to statistics given by national cancer institute in 2020, an estimated 1,806,590 new cases of cancer were diagnosed in the U.S. and 606,520 people passed away due to the disease. This surge in the incidences of cancer propel the growth of the industry in the coming years. Increase in awareness programs regarding the need for cancer immunotherapy is expected to help the market gain traction during the forecast period. However, the factors such as stringent regulations related to cancer immunotherapy are anticipated to hinder the growth of the cancer immunotherapy market. Government has better supervision over the use of immunotherapy and is also taking care of the clinical trials going on user the government norms, which has made it difficult to the companies to enter the industry and is hence expected to hinder the growth of the market. Also, high product developmental cost is anticipated to impede the growth of the cancer immunotherapy market.

Global Cancer Immunotherapy Market Segmentation

The cancer immunotherapy market is categorized into technology type, application, end-user, and region. By technology type, the market is divided into monoclonal antibodies, cytokines & immunomodulators, and others. Monoclonal antibodies held the largest share in 2020, owing to surge in usage of monoclonal antibodies for cancer immunotherapy as they exhibit different properties where immune system can be modulated and hence, they can activate or inhibit the molecules targeted on immune system. In addition, monoclonal antibodies also induce the antitumor immune response.

By application, the cancer immunotherapy market is segmented as lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, head & neck cancer, and other applications. The lung cancer market held the largest share in 2020 and is expected to lead the market during the analysis period owing to high incidence of lung cancer worldwide and surge in the awareness program regarding the need for early therapeutics of lung cancer.

On the basis of end user, the market is categorized into hospitals, cancer research centres and clinics. Hospitals held the largest market share of cancer immunotherapy market in 2020, and this segment is projected to show the highest growth rate during the analysis period due to the extensive use of cancer immunotherapy in the hospitals. Furthermore, higher preference toward hospitals is anticipated to boost the growth of the segment during the forecast period. Furthermore, hospitals segment would gain highest CAGR of about 14.7% in the forecast period. 

Region wise, the cancer immunotherapy market is analysed across North America, Europe, Asia-Pacific, and LAMEA. North America was the highest revenue contributor in 2020. This is attributed to the steep rise in amount of expenditure in healthcare, increased focus on maintaining best healthcare system, and increased incidence of cancer worldwide. However, Asia-Pacific is projected to grow with the highest CAGR during the analysis period, owing to rise in healthcare expenditure, surge in per capita income, and improvement in healthcare infrastructure. In addition, Europe is expected to gain second largest revenue share during the forecast period, owing to the development in the infrastructure in the region and rising incidences of cancer.

The key players operating in the global cancer immunotherapy market include Amgen, Inc., AstraZeneca, PLC, Bayer AG, Bristol-Myers Squibb Company, Eli Lily And Company, F. Hoffmann-La Roche, Ltd. (Genentech, Inc.), Pfizer, Inc., Johnson & Johnson (Janssen Global Services, LLC), Merck KGAA, and Novartis AG.